AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03454282 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FMD
Description: The Fasting Mimicking Diet (or FMD) consists in a 5-day plant-based, low-calorie (about 600 Kcal on day 1, followed by about 300 KCal/day on days 2 to 5), low-carbohydrate low-protein diet
Study NCT03816436 — intervention group
Intervention type: OTHER
Intervention: Follow- up (FU) assessment
Description: Follow- up (FU) assessment (clinical examination and patient questionnaires) at least 24 months after surgery (clavicular midshaft and lateral non- union treated by plate and iliac crest bone grafting)
Study NCT02710214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tissue Selective Estrogen Complex
Description: Once-daily dosing of Duavee for 8 weeks.
Study NCT02710214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once-daily dosing of placebo for 8 weeks
Study NCT00179673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 25 mg orally once daily on Days 1 to 21 of every 28-day cycle for up to 52 weeks or until disease progression developed
Study NCT04304274 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paravertebral block-ropivacaine
Description: Inject 25 ml 0.5% ropivacaine in the T8 paravertebral space followed with catheter insertion and continuous 0.2% ropivacaine infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h)
Study NCT04304274 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Paravertebral block-saline
Description: Inject 25 ml 0.9% saline in the T8 paravertebral space followed with catheter insertion and continuous 0.9% saline infusion(infusion rate: 0.125ml/kg/pulse,1pulse/h)
Study NCT04304274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: patient controlled analgesia with morphine
Description: Morphine was given as intravenous patient-controlled analgesia bolus: 1-2mg, lock time: 5min, 1h limitation: 8mg
Study NCT04304274 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: patient controlled analgesia with morphine
Description: Morphine was given as intravenous patient-controlled analgesia bolus: 1-2mg, lock time: 5min, 1h limitation: 8mg
Study NCT02959983 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eluxadoline
Description: Eluxadoline 100 mg oral tablets BID with food.
Study NCT00712114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HE3286
Description: HE3286 will be administered orally. Dosing will be 10 mg per day for 29 days.
Study NCT00712114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HE3286
Description: HE3286 will be administered orally. Dosing will be 20 mg per day for 29 days
Study NCT00712114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HE3286
Description: HE3286 will be administered orally. Dosing will be 40 mg per day for 29 days
Study NCT01971476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: volasertib
Description: intravenous administration on day 1of a treatment course
Study NCT03742960 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Sleep Restriction
Description: Participants will be instructed to go to bed 30 minutes later than their usual bedtime. On the other hand, wake up time will be unchanged resulting a nightly sleep restriction of 30 minutes. This protocol will be followed for two weeks.
Study NCT03988387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder and Resource Transfer (RRT)
Description: Participants who are randomized to the RRT arm will receive a discrete weekly SMS text (or voice message if participant is illiterate) to encourage healthy behaviors, study engagement and PrEP adherence. Messages will be a general message that the participant has selected and will not have any information identifying the participant as part of the study or describing the purpose of the study. An example text is Remember to look after yourself today, See you tomorrow. Participants will be requested to respond to the message with a brief answer. Participants will be advised that each answered text counts as a point toward resource transfer that can be redeemed at scheduled study visits in the form of a small gift, such as cosmetics, personal care items, accessories, or airtime.The value of the reward increases with points.
Study NCT03988387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daily oral PrEP (emtricitabine 200 mg/tenofovir 300 mg) [FTC/TDF]
Description: All participants will receive a one-month supply of daily oral PrEP (emtricitabine 200 mg/tenofovir 300 mg) \[FTC/TDF\] for the first month of enrollment.
Study NCT02959983 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching eluxadoline oral tablets BID with food.
Study NCT03860610 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Muscle strength test
Description: Muscle strength in knee flexion and extension and hip abduction will be tested using using a dynamometer (Biodex System 4 Pro: Biodex Medical Systems, Shirley, NY, USA)
Study NCT04220528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine/Tiggio
Description: Drug: Capecitabine/Tiggio~Radical chemoradiotherapy：Induction chemotherapy plus Concurrent chemoradiotherapy~Induction chemotherapy：Gemcitabine (1000mg/m2) D1 D8+ nida platinum (80mg/m2) D2 q3w ×3cycle~Concurrent chemoradiotherapy：IMRT was used for radiotherapy, during which D1 and D22 were given two cycles of single drug concurrent chemotherapy with nidapatin (100mg/m2).
Study NCT03860610 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Dynamic stability test during level and uphill walking
Description: Instrumented gait analysis on an overground walkway with two embedded force plates (Kistler force plate 9260AA6, Kistler AG, Winterthur, Switzerland; sampling rate 2400 Hz) and on a treadmill with an embedded plantar pressure plate (h/p/cosmos, Zebris FDM-T, Isny, Germany)
Study NCT03860610 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Postural stability test
Description: The overall stability index (OSI) will be assessed using the Biodex Balance System SD (Biodex Medical Systems, Inc., Shirley, NY, USA) and is determined by the variance in platform displacement from the horizontal plane.
Study NCT03860610 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: EuroQol Group Health questionnaire (EQ-5D-5L)
Description: Overall health will be assessed using the EQ-5D-5L health questionnaire
Study NCT03860610 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HOOS/ KOOS
Description: Site specific pain and function will be assessed with the Hip Osteoarthritis Outcome Score (HOOS) and Knee Injury and Osteoarthritis Outcome Score (KOOS) depending on the affected joint (hip or knee).
Study NCT03860610 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Muscle activity test
Description: Surface electrodes (Ag/AgCl, Noraxon, U.S.A. Inc., Scottsdale, AZ, USA: 10 mm diameter, 22 mm inter-electrode distance) will be placed bilaterally on glutaeus medius, vastus medialis, semitendinosus, tibialis anterior, gastrocnemius medialis, and peroneus longus muscles. Periods of muscle activity will be defined as intensity above 2 Standard Deviation (SD) of the resting Electromyography (EMG) signal. Duration of overlapping muscle activity between agonists and antagonists normalized to one gait cycle or of a balance test, respectively, will be determined.
Study NCT03860610 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Passive range of motion
Description: Passive range of motion will be assessed for ankle plantar-/dorsiflexion, knee flexion/extension and hip flexion/extension, ab/adduction, internal/external rotation using goniometers and recorded in degrees. The range between two maxima will be recorded.
Study NCT02280538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra-Articular Hyaluronic Acid
Study NCT02280538 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00964314 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: music
Description: Experimental Group one : Listening TCM five elements music therapy（TCMMT）based on conventional therapy in China.~Experimental Group two: Listening western music based on conventional therapy in China.~Control Group: no music therapy will be done.
Study NCT02000934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-659
Description: TAK-659 tablet
Study NCT00621959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levocetirizine dihydrochloride
Description: 5mg daily (oral tablet) for 14 days
Study NCT00621959 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0mg (matching oral tablet)for 14 days
Study NCT00590135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin (Lipitor)
Description: atorvastatin 40 mg by mouth once daily
Study NCT04250922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LAM561
Description: Subjects in Arm B will receive orally LAM561 during the Chemoradiation Phase.~Subjects in Arm B will receive LAM561 orally during the Maintenance (Adjuvant) Phase. Patients will continue to be administered with LAM561/Placebo after cycle 6 of the monotherapy phase until end of study. Adjuvant treatment will be discontinued upon determination of tumour progression as defined by RANO criteria, unacceptable toxicity, or refusal to continue study treatment.
Study NCT04250922 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TMZ
Description: TMZ will be administered at 75 mg/m2, orally, once daily, continuously from Day 1 of radiotherapy to the last day of radiation for a maximum of 49 days.~During the Maintenance (Adjuvant) Phase, all subjects will receive oral TMZ 150 - 200 mg/m2 once daily on Days 1 - 5 of each 28-day cycle for 6 cycles.
Study NCT04250922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMZ
Description: TMZ will be administered at 75 mg/m2, orally, once daily, continuously from Day 1 of radiotherapy to the last day of radiation for a maximum of 49 days.~During the Maintenance (Adjuvant) Phase, all subjects will receive oral TMZ 150 - 200 mg/m2 once daily on Days 1 - 5 of each 28-day cycle for 6 cycles.
Study NCT04250922 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: RT
Description: During the Chemoradiation Phase, all subjects will undergo focal RT, with one treatment given daily 5 days per week over approximately 6 weeks (and no more than 7 weeks).
Study NCT04250922 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: RT
Description: During the Chemoradiation Phase, all subjects will undergo focal RT, with one treatment given daily 5 days per week over approximately 6 weeks (and no more than 7 weeks).
Study NCT00646074 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Care Talk
Description: 6 conversational sessions
Study NCT02967432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin Topical Ointment
Description: Mupirocin ointment 1/2 inch ribbon applied topically to each nare and umbilicus twice daily for 5 days; repeat treatment courses possible.
Study NCT00964314 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music
Description: Experimental Group one : Listening TCM five elements music therapy（TCMMT）based on conventional therapy in China.~Experimental Group two: Listening western music based on conventional therapy in China.~Control Group: no music therapy will be done.
Study NCT00964314 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: music
Description: Experimental Group one : Listening TCM five elements music therapy（TCMMT）based on conventional therapy in China.~Experimental Group two: Listening western music based on conventional therapy in China.~Control Group: no music therapy will be done.
Study NCT02967432 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Petroleum Jelly
Description: Petroleum jelly ointment 1/2 inch ribbon applied topically to each nare and umbilicus twice daily for 5 days; repeat treatment courses possible.
Study NCT00921401 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma Feedback
Description: All participants will log in to the study Web site at least once a month and before all doctor visits. They will answer a series of questions and receive individualized feedback about the types of questions they should ask their doctor.
Study NCT00921401 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Asthma Feedback
Description: All participants will log in to the study Web site at least once a month and before all doctor visits. They will answer a series of questions and receive individualized feedback about the types of questions they should ask their doctor.
Study NCT01449019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exendin(9-39)amide
Description: intravenous infusion of exendin(9-39)
Study NCT01449019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Description: intravenous infusion of saline
Study NCT01449019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: duodenal meal
Description: duodenal perfusion of a meal
Study NCT00260689 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (rabbit)
Study NCT00260689 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (horse)
Study NCT00260689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Study NCT01449019 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: duodenal saline
Description: duodenal perfusion of saline
Study NCT04174638 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing and Education Based on Watson's Theory of Human Caring
Description: The intervention group received 15 minute motivational interviewing based on Watson's Theory of Human Caring once a month for 12 weeks and one session 30 minutes education with educational booklet based on Watson's Theory of Human Caring. The intervention performed before the hemodialysis session in a separate room in the hemodialysis unit.
Study NCT03924024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accelerated intermittent theta burst treatment
Description: All participants will receive accelerated intermittent theta-burst stimulation to the left DLPFC. Stimulation intensity will be standardized to 80% of resting motor threshold.~Stimulation will be delivered to L-DLPFC using the Brainsway stimulator.
Study NCT03403504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone Tamper Resistant
Description: Orally administered Oxycodone Tamper Resistant 10mg
Study NCT03403504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OXYCONTIN®
Description: Orally administered OXYCONTIN® Tablet 10 mg
Study NCT00848692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Two infusions of Rituximab 500 mg/m2 (max 1000 mg) given two weeks apart
Study NCT00848692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline (NaCl 0,9 %) (placebo)
Description: Two infusions of saline (NaCl 0,9 %) given two weeks apart
Study NCT03238144 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRF scan
Description: MRF with or without dynamic contrast-enhanced MRI scans.
Study NCT01142219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-arginine
Description: L-arginine was administered orally at a dose of 0.1g/kg/day during 6 months.
Study NCT01142219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Mannitol was administered orally at a dose of 01 g/kg/day for six months.
Study NCT02796924 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MagStim Rapid2 Transcranial Magnetic Simulation
Description: A non-invasive method of brain stimulation
Study NCT01967420 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive remediation
Description: CIRCuiTS is a computerised cognitive remediation program which consists of tasks to improve cognition, the use of strategy training and the teaching of generalisable community functioning skills.
Study NCT01967420 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive remediation
Description: CIRCuiTS is a computerised cognitive remediation program which consists of tasks to improve cognition, the use of strategy training and the teaching of generalisable community functioning skills.
Study NCT01967420 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social cognition training
Description: The social cognition training is a computerised program which aims to improve emotion recognition through a variety of lessons and games.
Study NCT03994926 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Eye Tracking after smoking Cannabis - HTC Vive Pro-Eye
Description: Device measures smooth eye pursuit and response to light flash after pt smokes cannabis
Study NCT03994926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis cigarette - 4.0% THC
Description: smoked cannabis 4.0% THC
Study NCT00260689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Study NCT02666027 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluid Intravenous Alert (FIVA) 'on'
Description: Fluid Intravenous Alert (FIVA) 'on' - The FIVA™ (EngenuityMED, Halifax, Canada) is a small, handheld, battery operated, device class I medical device in Canada (Figure 1). It is designed to alarm and alert the physician to change the IV bag when the fluid level in the chamber of the IV set is low. It also functions to stop the fluid flow through the gravity-fed tubing system when the alarm is triggered, preventing air from entering the IV tubing. We hypothesize that the FIVA would decrease the incidence of unnoticed dry IV bags during surgery, particularly when the operating room lights are dimmed and would therefore decrease the risks associated with undetected dry IV bags.
Study NCT01989637 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Strawberry Meal
Description: High-fat meal (50 g total fat) with 40 g freeze dried strawberry powder
Study NCT01989637 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Meal
Description: High-fat meal (50 g total fat) with a matched placebo powder containing no strawberry bioactives
Study NCT01313182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mupirocin calcium ointment, 2%
Description: Approximately one-half of the ointment from the single-use tube should be applied into 1 nostril and the other half into the other nostril twice daily (morning and evening) for 5 days.~After application, the nostrils should be closed by pressing together and releasing the sides of the nose repetitively for approximately 1 minute. This will spread the ointment throughout the nares.
Study NCT02666027 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Fluid Intravenous Alert (FIVA) 'off'
Description: The FIVA will be turned off. - The FIVA™ (EngenuityMED, Halifax, Canada) is a small, handheld, battery operated, device class I medical device in Canada. It is designed to alarm and alert the physician to change the IV bag when the fluid level in the chamber of the IV set is low. It also functions to stop the fluid flow through the gravity-fed tubing system when the alarm is triggered, preventing air from entering the IV tubing. We hypothesize that the FIVA would decrease the incidence of unnoticed dry IV bags during surgery, particularly when the operating room lights are dimmed and would therefore decrease the risks associated with undetected dry IV bags.
Study NCT02834312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estetrol
Description: All treatments (E4 \[2.5 mg, 5 mg, 10 mg, 15 mg\] capsule) will be administered once daily (QD) per os for at least 12 consecutive weeks until the last biological assessments (Day 90 maximum) have been performed.
Study NCT02479477 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesio therapy
Description: during for fifteen minutes the nursing assistants will perform stretching exercises and muscle relaxation of large muscle groups the orthostatic position
Study NCT00793234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TB-402
Description: TB-402 administered as single bolus 18-24 post total knee replacement surgery.
Study NCT01313182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3M Skin and Nasal Antiseptic
Description: The solution is applied to for 30 seconds to each nostril twice for a total of 2 minutes. The solution is applied by rotating the applicator around the circumference of the nostril for 15 seconds and then rotating the applicator in the anterior nares for 15 seconds.
Study NCT03275896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Descemet Membrane Transplantation
Description: The diseased host Descemet membrane will first be stripped, as per a standard Descemet Stripping Automated Endothelial Keratoplasty surgery. A cadaveric, acellular Descemet membrane graft will then be harvested and transplanted onto the host.
Study NCT00793234 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Enoxaparin 40mg/day sc injection for at least 10 days post-surgery
Study NCT01618513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sandostatin® LAR
Description: Intramuscular injections, dosage based on either GH or IGF-I levels.
Study NCT04428905 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine
Description: Participate in telehealth sessions
Study NCT02072057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib